FMD K&L Joins with iMEDGlobal in International CRO Merger

FMD K&L, a US-China clinical CRO, announced plans to merge with iMEDGlobal, a US-India pre-clinical CRO. The two companies said their complementary services and geographical focuses, plus operational synergies, would make a stronger company. FMD K&L was also formed by a merger: in 2014, Fountain Medical Development of Beijing combined its China-Southeast Asia clinical operations with K&L, a US company specializing in data management and regulatory submissions. FMD remains the parent while FMD K&L is the subsidiary. More details.... Share this with colleagues: // //